Abstract:Abstract Intro: Immune checkpoint inhibition (ICI) for metastatic unresectable melanoma has markedly improved survival, and has shown benefit as adjuvant (AT) and neoadjuvant (NAT) therapy. Although ICI treatments confer survival benefit, they frequently induce immune-related adverse events (irAEs), which are a substantial clinical problem, particularly in AT/NAT, where ICI is used in less advanced disease to prevent recurrence. As such, the biomarkers predicting irAE risk, in particular in AT/NAT, are urgently needed to improve patient outcomes. Methods: We assessed RNA from pre-treatment peripheral CD4+ and CD8+ T cells from adjuvant clinical trial patients (CheckMate-915; n=212 patients) treated with Nivolumab (n=130) or Ipilimumab/Nivolumab (Combo) (n=82). We performed RNA-seq differential expression analysis to identify baseline differences in the immune profiles of patients with no/mild toxicity (grade 0-2) versus severe toxicity (grade 3-5). Results: Gene ontology analysis of the differentially expressed genes (DEGs) among those with severe toxicity reveals significant enrichment of immune-related pathways (IL-2, IFN-gamma, T-cell receptors, Toll-like receptors). These are shared among cell types (CD4+/CD8+) and between treatments (Nivo/Combo). From predicted DEG protein-protein interactions, we identified a treatment- and cell-type-specific expression signature associated with irAE development in CD4+ cells from Combo-treated patients. This signature, involving genes in the spleen tyrosine kinase (SYK) pathway, correctly predicts severe irAE patients with 73% accuracy (chi-squared p-value=0.001). The signature also identifies patients with mild to moderate irAEs in organ systems previously found in autoimmune traits to be associated with SYK upregulation (including skin, GI, liver, and pancreas), with 96% of all predicted patients experiencing at least one of these SYK-related toxicities, and 79% experiencing two or more. Importantly, the signature is not associated with disease recurrence (p=0.79). Conclusions: We have identified baseline expression differences in key immune pathways in peripheral T cells from ICI-treated patients with severe irAEs, and defined an SYK-related gene signature correctly identifying over half of severe irAE patients in the Combo-treated cohort. This finding aligns with our previous work linking anti-CTLA-4 irAEs with a germline variant associated with high SYK expression. This gene signature may not only serve as a baseline biomarker of severe irAEs, but it may also help guide treatment decisions, reducing toxicity while retaining efficacy, which will be particularly important in the adjuvant setting. Citation Format: Kelsey R. Monson, Robert Ferguson, Joanna Handzlik, Jiahan Xiong, Sasha Dagayev, Leah Morales, Vylyny Chat, Anabelle Bunis, Chaitra Sreenivasaiah, Sonia Dolfi, Daniel Tenney, Iman Osman, Jeffrey Weber, Tomas Kirchhoff. Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1185.

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy

Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy

Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.

Association Between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors.

Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).

Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma

Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors

Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias

Abstract 1185: Novel association of an autoimmune-related axis and anti-CTLA-4-based toxicities in adjuvant immunotherapy-treated melanoma patients

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Incidence of Immune-Related Adverse Events and Its Association with Treatment Outcomes: the MD Anderson Cancer Center Experience

Analysis of Immune-Related Adverse Events and Its Correlation with Efficacy of Anti-Pd-1 Monotherapy in Advanced Non-Small Cell Lung Cancer

Impact of immune-related adverse events (irAEs) on PD-1/L1 inhibitors efficacy in advanced esophageal cancer.

Association of Immune-Related Adverse Events with Immune Checkpoint Inhibitor Efficacy in Pancancer.